UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Victor_BTS_1280x960

    Apr

    25

    UCB’s Dr. Victor Sloan Shares His Commitment to Go Boldly

    Dr. Victor Sloan, UCB’s VP & Development Strategy Lead (immunology), was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign. Learn more about Dr. Sloan’s work and his motivation to find groundbreaking solutions.

    Research_for_blog_post_4.20.18_1280x960

    Apr

    20

    UCB’s Commitment in Neurology

    Today, we announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),1 an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

    blog_announcement_crop_002

    Apr

    20

    Press Release: UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

    UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

    bigger-Parkinsons-Stat-with-Logo--source-NEW-WITH-LOGO

    Apr

    19

    UCB Celebrates Parkinson’s Disease Awareness Month

    April is Parkinson’s Awareness Month. To honor those living with Parkinson’s disease (PD), we’re spreading awareness about the disease and sharing some of our favorite stories of inspiration.

    Blog_Photo_1280x960

    Apr

    16

    Welcome to UCB USA

    As the U.S. affiliate of UCB, a global biopharmaceutical company, we are excited to be relaunching UCB-USA.com and a blog with news on UCB in the U.S.

    UCB_campus_1280x960

    Apr

    13

    UCBCares is Dedicated to Providing Caring Experiences

    UCBCares® is UCB, Inc.'s single source solution center in the U.S. dedicated to providing exceptional caring experiences and solutions for all incoming inquiries to UCB from patients, caregivers, and healthcare providers.

    446_LaboPics-HR.jpg_1280x960

    Apr

    05

    Press Release: UCB strengthens research capabilities with acquisition

    UCB strengthens research capabilities with acquisition of Element Genomics, a Duke University biotech spin-off